The Combination of Ophthalmologic Tests and EEG Imaging as a New Biomarker for Alzheimer's Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Mild Cognitive Impairment
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- OCT retinal and choroidal thickness
- Last Updated
- 5 years ago
Overview
Brief Summary
Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with great social impact. It is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the pathophysiology of the disease. Meantime, EEG resting state has also demonstrated significant change in patients with AD in neuroscience research area. Thus, the combination of these sensitive biomarkers would lead to a potential new biomarker for detection of AD, which has higher specificity and sensitivity.
Investigators
Jin Yuan
assistant dean
Zhongshan Ophthalmic Center, Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of Alzheimer's Disease
Exclusion Criteria
- •neurologic disorders
- •psychiatric disorders
Outcomes
Primary Outcomes
OCT retinal and choroidal thickness
Time Frame: 2 days
retinal structural anatomy
Retinal Photography vascular caliber
Time Frame: 2 days
use Retinal Photography to detect vascular caliber
functional connection strength in the brain network
Time Frame: 7 days
record resting-state EEG, use graph theory to calculate the functional connection strength